At a glance
ClinicalIndex Comparison Record- ✓Clinically significant lipodystrophy identified by study physician as absence of fat outside normal range and/or disfiguring to patient
- ✓Circulating leptin <12.0 ng/ml in females, <8.0 ng/ml in males (or <6 ng/mL in children 6 months-5 years) measured by Linco assay after overnight fast
- ✓At least one metabolic abnormality: diabetes (per 2007 ADA criteria), fasting insulin >30 microunits/ml, or fasting triglycerides >200 mg/dL or postprandial triglycerides >500 mg/dL
- ✓Age ≥6 months
- ✕Pregnant women, women of reproductive age without effective birth control, or women nursing/lactating within 6 weeks of completing nursing
- ✕Known infectious liver disease
- ✕Known HIV infection
- ✕Current alcohol or substance abuse
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy
In Brief
A Phase 2 clinical trial evaluating Metreleptin for Lipodystrophy. Completed, enrolled 103 participants across 1 site.
Detailed Summary
This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss of fat cells. They also lack the hormone leptin, which is produced by fat cells. The leptin deficiency usually causes high blood lipid (fat) levels and insulin resistance that may lead to diabetes. Patients may have hormone imbalances, fertility problems, large appetite, and liver disease due to fat accumulation. Patients age greater than or equal to 6 months with significant lipodystrophy may be eligible for this study. Participants will be admitted to the NIH Clinical Center for 10 days for the following studies before beginning 12 months of leptin therapy: * Insulin tolerance test * Ultrasound of the liver and, if abnormalities are found, possibly liver biopsies. * Fasting blood tests * Resting metabolic rate * Magnetic resonance imaging of the liver and other organs, and of muscle and fat. * Pelvic ultrasound in women to detect ovarian cysts. * Estimation of body fat * Oral glucose tolerance test * Intravenous glucose tolerance test * Appetite level and food intake * Hormone function tests * Questionnaires to assess activity and mood * 24-hour urine collections Additional studies may include blood tests for genetic studies of lipodystrophy, a muscle biopsy to study muscle proteins involved in regulating energy expenditure before and after leptin replacement, and examination of a surgical specimen (if available) to study molecules that may be involved in energy storage and use. When the above tests are completed, leptin therapy begins. The drug is injected under the skin twice a day for 4 months and then once a day, if feasible. The dose is increased at the 1- and 2-month visits. Follow-up visits at 1, 2, 4, 6, 8 and 12 months after therapy starts include a physical examination, blood tests and a meeting with a dietitian. At the end of 12 months, all baseline studies described above are repeated. Patients record their symptoms weekly throughout the study. Those with diabetes measure their blood glucose levels daily before each meal and at bedtime.
Study Details
Timeline
Interventions
Drug treatment